Read in PDF
Lund, Sweden, 17th of July 2017 - Xintela AB (publ) announces that the company has recruited Liselotte Theorell as Director Product Development and Quality Management. The recruitment is an important step towards the production of stem cells under GMP (Good Manufacturing Practice) for upcoming clinical studies.
"Liselotte is one of few persons in Sweden who possess such extensive competence in quality management in combination with drug development, including quality systems for the development of cell and tissue therapies. Her experiences will be of great importance when Xintela now takes the next step to produce stem cells for clinical studies on horses and humans. I warmly welcome her to the team," says Xintelas CEO Evy Lundgren-Åkerlund.
Liselotte Theorell has broad experience of drug development, production and quality management, and has been responsible for the establishment of quality management systems for GMP, GLP (Good Laboratory Practice) and GCP (Good Clinical Practice) – in companies such as Cellaviva AB, SentoClone AB, Biovitrum AB and Moberg Pharma AB. Initially, Liselotte Theorell will focus on establishing procedures for GMP production of Xintela’s stem cells for upcoming clinical studies. In addition, she will work on developing Xintela’s quality management system and procedures for drug safety. Liselotte Theorell will also assist the company in the process of applying for necessary permissions from the Swedish Medical Products Agency (Läkemedelsverket).
"I am impressed with Xintela's ambitions and how far they have come in such a short period of time. Xintela has a very interesting technology for the development of safe and effective stem cell products and I’m really looking forward to contributing to the development work," says Liselotte Theorell.
Liselotte Theorell will start on 1th of August 2017.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se
For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se
About Xintela
Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. XINMARK® is also used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common and aggressive form of brain tumors in adults. Positive preclinical results from cell studies and animal model have shown that the antibody has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 17th of July 2017, at 10.30 CET.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
CEO Evy Lundgren-Åkerlund presents the company at ProHearings Capital Market Day in Stockholm on June 1, 2023.
Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).
